Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 59

1.

[Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease].

Pérez A, González Blanco C, Hernández-Presa MÁ, Chaves J.

Endocrinol Nutr. 2011 Jun-Jul;58(6):283-90. doi: 10.1016/j.endonu.2011.03.005. Spanish.

PMID:
21641286
[PubMed - indexed for MEDLINE]
2.

Management of dyslipidemia in diabetes.

Solano MP, Goldberg RB.

Cardiol Rev. 2006 May-Jun;14(3):125-35. Review.

PMID:
16628021
[PubMed - indexed for MEDLINE]
3.

Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

Nesto RW.

Am J Cardiovasc Drugs. 2005;5(6):379-87. Review.

PMID:
16259526
[PubMed - indexed for MEDLINE]
4.

Management of cardiovascular risk in patients with type 2 diabetes mellitus as a component of the cardiometabolic syndrome.

Ferdinand KC.

J Cardiometab Syndr. 2006 Spring;1(2):133-40. Review.

PMID:
17679832
[PubMed - indexed for MEDLINE]
5.

Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.

Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.

Am J Cardiovasc Drugs. 2007;7(1):39-58. Review. Erratum in: Am J Cardiovasc Drugs. 2007;7(4):302.

PMID:
17355165
[PubMed - indexed for MEDLINE]
6.

Management of dyslipidemia in people with type 2 diabetes mellitus.

Dunn FL.

Rev Endocr Metab Disord. 2010 Mar;11(1):41-51. doi: 10.1007/s11154-010-9132-6. Review.

PMID:
20221703
[PubMed - indexed for MEDLINE]
7.

Pharmacologic treatment of type 2 diabetic dyslipidemia.

Moon YS, Kashyap ML.

Pharmacotherapy. 2004 Dec;24(12):1692-713. Review.

PMID:
15585439
[PubMed - indexed for MEDLINE]
8.

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.

Keating GM.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Review.

PMID:
21675801
[PubMed - indexed for MEDLINE]
9.

High cardiovascular risk in patients with diabetes and the cardiometabolic syndrome: mandate for statin therapy.

Gonzalez GL, Manrique CM, Sowers JR.

J Cardiometab Syndr. 2006 Summer;1(3):178-83. Review.

PMID:
17679817
[PubMed - indexed for MEDLINE]
10.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
[PubMed - indexed for MEDLINE]
Free Article
11.

[Lipid management--treatment goal and strategy].

Koshiyama H.

Nihon Rinsho. 2006 Nov;64(11):2102-6. Review. Japanese.

PMID:
17087303
[PubMed - indexed for MEDLINE]
12.

Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus.

Wanner C, Krane V.

Kidney Blood Press Res. 2011;34(4):209-17. doi: 10.1159/000326849. Epub 2011 Jun 21. Review.

PMID:
21691123
[PubMed - indexed for MEDLINE]
13.

Lipid control in patients with diabetes mellitus.

Betteridge DJ.

Nat Rev Cardiol. 2011 May;8(5):278-90. doi: 10.1038/nrcardio.2011.23. Epub 2011 Mar 15. Review.

PMID:
21403658
[PubMed - indexed for MEDLINE]
14.

[Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents].

Soska V.

Vnitr Lek. 2011 Mar;57(3):313-6. Review. Czech.

PMID:
21495414
[PubMed - indexed for MEDLINE]
15.

Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.

Hobbs FD.

Int J Cardiol. 2006 Jun 16;110(2):137-45. Epub 2005 Nov 11. Review.

PMID:
16289373
[PubMed - indexed for MEDLINE]
16.

Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.

Falko JM, Moser RJ, Meis SB, Caulin-Glaser T.

Curr Diabetes Rev. 2005 May;1(2):127-35. Review.

PMID:
18220588
[PubMed - indexed for MEDLINE]
17.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program.

J Am Coll Cardiol. 2004 Aug 4;44(3):720-32. Review.

PMID:
15358046
[PubMed - indexed for MEDLINE]
Free Article
18.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; Coordinating Committee of the National Cholesterol Education Program.

Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):e149-61. Review.

PMID:
15297292
[PubMed - indexed for MEDLINE]
Free Article
19.

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ; National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association.

Circulation. 2004 Jul 13;110(2):227-39. Review. Erratum in: Circulation. 2004 Aug 10;110(6):763.

PMID:
15249516
[PubMed - indexed for MEDLINE]
Free Article
20.

Dyslipidemia in type 2 diabetes mellitus.

Gadi R, Samaha FF.

Curr Diab Rep. 2007 Jun;7(3):228-34. Review.

PMID:
17547840
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk